SJP-1601

N/A

Report date: 2025/01/26 16:10:20
NME

Base Information

Drug NameSJP-1601
Drug Alias NameSJP-1601
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-Raf kinase inhibitorsVascular endothelial growth factor receptor 2 antagonistsSerine/threonine-protein kinase B-raf inhibitors +[4] 
TargetsC-Raf kinaseVascular endothelial growth factor receptor 2Serine/threonine-protein kinase B-raf +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSamjin Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIncheon National UniversitySamjin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A